How to create a 5-year M&A plan for dealing with patent cliffs - ERP Spain.com - España y América Latina

A patent cliff represents a severe drop in revenue when the patents behind one, or more of a company's successful products expires. This opens up opportunities for competitors to develop, replicate and sell these products, often at lower prices. US biopharmaceutical company Celgene recently had their application for regulatory approval on a new drug denied by the FDA- as a result, the company is facing major market share and revenue losses, and is facing a phenomenal patent cliff. Furthermore, research from EvaluatePharma reports that an estimated $250 billion in projected sales is at risk between 2018-2024 as many drugs lose exclusivity. We are very excited to welcome back Jurgen Vollrath, President of Exponential Technology Counsel, and customer of PatSnap. ET Counsel, advise clients on IP strategy & business alignment to ensure the most successful M&A and exit outcomes. In this webinar, Jurgen will be discussing: - Risk vs. reality when it comes to patent cliffs - How to create a 5-year M&A plan for your organisation - How to find potential acquisition targets - Predicting the potential impact a patent cliff could have on your business.